A Phase III Double-Blind, Randomized Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of ZOSTAVAX administered comcomitantly versus Non-concomitantly with PNEUMOVAX 23 in subjects 60 years of age and older

Woman and Man

| Country :
| organs :
| Specialty :

Extract

1. To determine whether ZOSTAVAX™ administered concomitantly with PNEUMOVAX™ 23 elicits a VZV antibody response that is noninferior to that of ZOSTAVAX™ administered nonconcomitantly. 2. To demonstrate whether ZOSTAVAX™ elicits an acceptable VZV antibody response when administered concomitantly with PNEUMOVAX™ 23. 3. To assess whether PNEUMOVAX™ 23 administered concomitantly with ZOSTAVAX™ elicits serotype-specific pneumococcal antibody responses for serotypes 3, 14, 19A, and 22F that are noninferior to those of PNEUMOVAX™ 23 administered nonconcomitantly

Inclusion criteria

herpes zoster, pneumococcal infection

Kusajili – Clinical trials directory

A Phase III Double-Blind, Randomized Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of ZOSTAVAX administered comcomitantly versus Non-concomitantly with PNEUMOVAX 23 in subj...